UK-based AI imaging solutions provider Brainomix has partnered with German pharmaceutical company Boehringer Ingelheim to enhance care for US patients with fibrosing lung disease.

The collaboration will leverage Brainomix’s 360 e-Lung AI imaging analysis on routine CT scans to speed up diagnosis and improve treatment access for fibrosing lung disease patients.

Under the collaboration, Brainomix will deploy its FDA-approved e-Lung software at top pulmonology centres and their networks of referring sites across the US.

The initiative aims to validate the potential of the e-Lung system to optimise patient care pathways and improve outcomes for fibrosing lung disease patients.

Brainomix CEO and co-founder Michalis Papadakis said: “There is an urgent need to improve the identification of people with fibrosing lung disease. This will enable earlier access to specialist care and the opportunity for faster initiation of treatment, which can slow the worsening of the disease.

“The patient pathway for people with fibrosing lung disease is currently fragmented and, it can take many years for a patient to be diagnosed.”

According to Brainomix, pulmonary fibrosis is a progressive and severe chronic lung condition.

Patients with pulmonary fibrosis may live only five years without treatment, after being diagnosed, facing up to a two-year wait for a diagnosis.

Early initiation of the treatment is crucial for optimal survival in fibrosing lung disease, but identifying eligible patients through imaging is challenging, even for experts, said Brainomix.

Brainomix said that the partnership will leverage both companies’ experience and expertise in stroke to develop a network model of care for patients with fibrosing lung disease.

Also, it will help generate real-world evidence to enhance the opportunities with the e-Lung system, improving outcomes for patients and their families.

In May this year, Brainomix received FDA approval for its e-Lung solution, and launched, a series of new studies to determine the prognostic value of its lung imaging biomarkers.

The studies underlined its expanding partnerships in Life Sciences and collaborations with top lung research centres, said the AI imaging solutions provider.

Boehringer Ingelheim global therapeutic areas head Ioannis Sapountzis said: “At Boehringer Ingelheim, we know how critical early and confident detection of progression is for people living with fibrosing lung disease.

“We believe that Brainomix 360 e-Lung has the potential to revolutionize the diagnostic landscape and thereby enable earlier treatment decisions at a pivotal stage of the patient’s journey. This can ultimately improve patient outcomes and quality of life of those affected.”